These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 33208875)

  • 81. The clinical value of the combined detection of sEGFR, CA125 and HE4 for epithelial ovarian cancer diagnosis.
    Li Y; Wang ZC; Luo L; Mu CY; Xu J; Feng Q; Li SB; Gu B; Ma P; Lan T
    Eur Rev Med Pharmacol Sci; 2020 Jan; 24(2):604-610. PubMed ID: 32016961
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Clinical value of a new serum tumor marker, CA125II, in gynecologic disease: comparison with CA125.
    Tamakoshi K; Kikkawa F; Hasegawa N; Ishikawa H; Mizuno K; Kawai M; Tomoda Y
    Gynecol Obstet Invest; 1995; 39(2):125-9. PubMed ID: 7737582
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Evaluation of the accuracy of serum human epididymis protein 4 in combination with CA125 for detecting ovarian cancer: a prospective case-control study in a Korean population.
    Kim YM; Whang DH; Park J; Kim SH; Lee SW; Park HA; Ha M; Choi KH
    Clin Chem Lab Med; 2011 Mar; 49(3):527-34. PubMed ID: 21320028
    [TBL] [Abstract][Full Text] [Related]  

  • 84. HE4, CA125 and risk of ovarian malignancy algorithm (ROMA) as diagnostic tools for ovarian cancer in patients with a pelvic mass: An Italian multicenter study.
    Romagnolo C; Leon AE; Fabricio ASC; Taborelli M; Polesel J; Del Pup L; Steffan A; Cervo S; Ravaggi A; Zanotti L; Bandiera E; Odicino FE; Scattolo N; Squarcina E; Papadakis C; Maggino T; Gion M
    Gynecol Oncol; 2016 May; 141(2):303-311. PubMed ID: 26801941
    [TBL] [Abstract][Full Text] [Related]  

  • 85. No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting.
    Jacob F; Meier M; Caduff R; Goldstein D; Pochechueva T; Hacker N; Fink D; Heinzelmann-Schwarz V
    Gynecol Oncol; 2011 Jun; 121(3):487-91. PubMed ID: 21420727
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Diagnostic performances of CA125, HE4, and ROMA index in ovarian cancer.
    Dikmen ZG; Colak A; Dogan P; Tuncer S; Akbiyik F
    Eur J Gynaecol Oncol; 2015; 36(4):457-62. PubMed ID: 26390703
    [TBL] [Abstract][Full Text] [Related]  

  • 87. The Establishment of an HE4-CLIA Method and the Combined Analysis of HE4 and CA125 in Ovarian Cancer.
    Zhang Q; Wang CR; Yu JP; Ma Q; Xu WW
    J Clin Lab Anal; 2016 Sep; 30(5):709-18. PubMed ID: 26990679
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Evaluation of HE4 as an extrabiomarker to CA125 to improve detection of ovarian carcinoma: is it time for a step forward?
    Azzam AZ; Hashad DI; Kamel NA
    Arch Gynecol Obstet; 2013 Jul; 288(1):167-72. PubMed ID: 23361457
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Using a panel of multiple tumor-associated antigens to enhance the autoantibody detection in the immunodiagnosis of ovarian cancer.
    Wang P; Qin J; Ye H; Li L; Wang X; Zhang J
    J Cell Biochem; 2019 Mar; 120(3):3091-3100. PubMed ID: 30484895
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Simultaneous Measurement of 92 Serum Protein Biomarkers for the Development of a Multiprotein Classifier for Ovarian Cancer Detection.
    Skubitz APN; Boylan KLM; Geschwind K; Cao Q; Starr TK; Geller MA; Celestino J; Bast RC; Lu KH; Koopmeiners JS
    Cancer Prev Res (Phila); 2019 Mar; 12(3):171-184. PubMed ID: 30709840
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Development of multiplexed bead-based immunoassays for the detection of early stage ovarian cancer using a combination of serum biomarkers.
    Kim YW; Bae SM; Lim H; Kim YJ; Ahn WS
    PLoS One; 2012; 7(9):e44960. PubMed ID: 22970327
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Diagnostic value of serum HE4 in endometrial cancer: a meta-analysis.
    Bie Y; Zhang Z
    World J Surg Oncol; 2014 May; 12():169. PubMed ID: 24885319
    [TBL] [Abstract][Full Text] [Related]  

  • 93. A Prospective Evaluation of Early Detection Biomarkers for Ovarian Cancer in the European EPIC Cohort.
    Terry KL; Schock H; Fortner RT; Hüsing A; Fichorova RN; Yamamoto HS; Vitonis AF; Johnson T; Overvad K; Tjønneland A; Boutron-Ruault MC; Mesrine S; Severi G; Dossus L; Rinaldi S; Boeing H; Benetou V; Lagiou P; Trichopoulou A; Krogh V; Kuhn E; Panico S; Bueno-de-Mesquita HB; Onland-Moret NC; Peeters PH; Gram IT; Weiderpass E; Duell EJ; Sanchez MJ; Ardanaz E; Etxezarreta N; Navarro C; Idahl A; Lundin E; Jirström K; Manjer J; Wareham NJ; Khaw KT; Byrne KS; Travis RC; Gunter MJ; Merritt MA; Riboli E; Cramer DW; Kaaks R
    Clin Cancer Res; 2016 Sep; 22(18):4664-75. PubMed ID: 27060155
    [TBL] [Abstract][Full Text] [Related]  

  • 94. High Levels of C-Reactive Protein Are Associated with an Increased Risk of Ovarian Cancer: Results from the Ovarian Cancer Cohort Consortium.
    Peres LC; Mallen AR; Townsend MK; Poole EM; Trabert B; Allen NE; Arslan AA; Dossus L; Fortner RT; Gram IT; Hartge P; Idahl A; Kaaks R; Kvaskoff M; Magliocco AM; Merritt MA; Quirós JR; Tjonneland A; Trichopoulou A; Tumino R; van Gils CH; Visvanathan K; Wentzensen N; Zeleniuch-Jacquotte A; Tworoger SS
    Cancer Res; 2019 Oct; 79(20):5442-5451. PubMed ID: 31462430
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Diagnostic and prognostic significance of serum CD26 level in Asian women with high-grade serous ovarian carcinoma.
    Shao S; Wang C; Tian J; Zhang H; Wang S; Du Y
    Future Oncol; 2019 Jun; 15(16):1863-1871. PubMed ID: 31140312
    [No Abstract]   [Full Text] [Related]  

  • 96. Cytomegalovirus and systemic inflammation at time of surgery is associated with worse outcomes in serous ovarian cancer.
    Wesley E; Uppendahl LD; Felices M; Dahl C; Messelt A; Boylan KLM; Skubitz APN; Vogel RI; Nelson HH; Geller MA
    Gynecol Oncol; 2021 Jan; 160(1):193-198. PubMed ID: 33168306
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Diagnostic value of carbohydrate antigen 72-4 combined with carbohydrate antigen 15.3 in ovarian cancer, cervical cancer and endometrial cancer.
    Li M; Men X; Zhang X
    J BUON; 2020; 25(4):1918-1927. PubMed ID: 33099933
    [TBL] [Abstract][Full Text] [Related]  

  • 98. A combined biomarker panel shows improved sensitivity and specificity for detection of ovarian cancer.
    Mao L; Tang Y; Deng MJ; Huang CT; Lan D; Nong WZ; Li L; Wang Q
    J Clin Lab Anal; 2022 Feb; 36(2):e24232. PubMed ID: 34995016
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Detection of MCM5 as a novel non-invasive aid for the diagnosis of endometrial and ovarian tumours.
    Stockley J; Akhand R; Kennedy A; Nyberg C; Crosbie EJ; Edmondson RJ
    BMC Cancer; 2020 Oct; 20(1):1000. PubMed ID: 33059604
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Multispectral label-free Raman spectroscopy can detect ovarian and endometrial cancer with high accuracy.
    David S; Plante A; Dallaire F; Tremblay JP; Sheehy G; Macdonald E; Forrest L; Daneshmand M; Trudel D; Wilson BC; Hopkins L; Murugkar S; Vanderhyden B; Leblond F
    J Biophotonics; 2022 Feb; 15(2):e202100198. PubMed ID: 34837331
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.